ArticleFrontiers in pharmacology2025
A thermo-sensitive peptide hydrogel loaded with paclitaxel and antimony nanosheets for synergistic photothermal-chemotherapeutic treatment of breast cancer.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antitumor Evaluation of Rhenium-188 and Paclitaxel Co-Delivered via Thermosensitive Hydrogel in a Hepatocellular Carcinoma Animal Model.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Breast cancer is one of the most common cancers in the world. Paclitaxel (PTX), a potent chemotherapeutic agent, is widely used in cancer treatment but suffers from poor aqueous solubility and systemic toxicity. Methods: In this study, we developed a thermo-sensitive peptide, TSP-5, which forms a stable hydrogel at 37 °C and dissociates upon heating to 45 °C to facilitate drug release. The hydrogel was co-loaded with PTX and photothermal agent antimony nanosheets (AM) for targeted delivery to tumor sites. Under near-infrared (NIR) laser irradiation, AM rapidly elevated the local temperature due to its high photothermal conversion efficiency, triggering hydrogel dissolution and subsequent PTX release. Simultaneously, AM-mediated photothermal therapy (PTT) contributed to tumor cell ablation. Results: Both Discussion: The findings highlight its potential as a promising platform for localized drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.